Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Chronic Hepatitis Delta
- Main trialPhase 1/2
- “The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants. The primary objective of Phase 2 of this study is to evaluate the efficacy and safety of the multiple escalating doses of GS-4321 in participants…”In the company’s words, NCT07096193 on ClinicalTrials.gov
Other drugs for Chronic Hepatitis Delta
- ElebsiranVir Biotechnology, Inc. · Phase 3
- TobevibartVir Biotechnology, Inc. · Phase 3
- BrelovitugMirum Pharmaceuticals, Inc. · Phase 2/3
- HepalatideShanghai HEP Pharmaceutical Co., Ltd. · Phase 3
- RBD1016Ribocure Pharmaceuticals AB · Phase 2
Coming up1
- Jan 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jan 2030 | Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026